Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026.
Fourth Quarter FY2026 Highlights
- Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million. Full year organic and reported revenue remained flat at $1.2 billion.
- GAAP EPS increased to $0.35 from $(0.11) one year ago. Delivered adjusted EPS was $0.52, down from $0.53 one year ago. Full year GAAP EPS increased to $1.16 versus $0.46 one year ago. Full year adjusted EPS was $1.93, up from $1.92 one year ago.
- As previously announced on June 25, 2026, Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion.
"Bio-Techne ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research and diagnostic workflows," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We continue to make progress toward completing Bio-Techne's acquisition by Merck KGaA, Darmstadt, Germany, and look forward to the opportunities this transaction is expected to create for our customers and employees."
Conference Call
In light of the announced transaction with Merck KGaA, Darmstadt, Germany, Bio-Techne is no longer holding investor conference calls for quarterly results.
Fourth Quarter Fiscal 2026
Revenue
Net sales for the fourth quarter increased 1% to $321.2 million. Organic growth increased 3% compared to the prior year. Non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2% and foreign currency exchange did not have a material impact.
GAAP Earnings Results
GAAP EPS was $0.35 per diluted share versus $(0.11) in the same quarter last year. GAAP operating income for the fourth quarter of fiscal 2026 was $74.3 million compared to an operating loss of $23.9 million in the fourth quarter of fiscal 2025. GAAP operating margin was 23.1% compared to (7.5)% in the fourth quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year.
Non-GAAP Earnings Results
Adjusted EPS decreased to $0.52 per diluted share compared to $0.53 in the same quarter last year. Adjusted operating income increased to $103.4 million in the fourth quarter of fiscal 2026 compared to $101.3 million in the fourth quarter of fiscal 2025. Adjusted operating margin was 32.2% for the fourth quarter of fiscal 2026 compared to 32.0% in the fourth quarter of fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture, partially offset by unfavorable product mix.
Full Year Fiscal 2026
Revenue
Net sales for the full year fiscal 2026 remained flat from the prior year at $1.2 billion. Organic revenue remained flat from the prior year. Foreign currency exchange had a favorable impact of 2% and a business held-for-sale had an unfavorable impact of 2%.
GAAP Earnings Results
GAAP EPS was $1.16 per diluted share, compared to $0.46 last fiscal year. GAAP operating income for full year fiscal 2026 increased 146% to $251.9 million, compared to $102.3 million in the full year fiscal 2025. GAAP operating margin was 20.7% compared to 8.4% in the full year fiscal 2025. GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year, a non-recurring arbitration award in the prior year, and a recovery of assets held-for-sale.
Non-GAAP Earnings Results
Adjusted EPS increased to $1.93 per diluted share, compared to $1.92 last fiscal year. Adjusted operating income for fiscal 2026 increased 1% to $386.1 million, compared to $383.6 million for fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture.
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.
Protein Sciences Segment
The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The Protein Sciences segment's fourth quarter fiscal 2026 net sales were $231.2 million, an increase of 2% from $226.5 million in the fourth quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's operating results for both periods presented. Organic revenue increased 1% for the fourth quarter of fiscal 2026, with foreign currency exchange having a favorable impact of 1%. The Protein Sciences segment's operating margin decreased to 42.0% in the fourth quarter of fiscal 2026 compared to 43.6% in the fourth quarter of fiscal 2025. The segment's operating margin decreased primarily due to unfavorable volume and product mix.
Protein Sciences segment's full year fiscal 2026 net sales were $874.6 million, an increase of 1% from $870.2 million for full year fiscal 2025. Organic revenue for the segment decreased 1% for the fiscal year, with foreign currency exchange having a favorable impact of 2%. Protein Sciences segment's operating margin was 41.1% in fiscal 2026 compared to 42.6% in fiscal 2025. The segment's operating margin was impacted by unfavorable volume and product mix.
Diagnostics and Spatial Biology Segment
The Company's Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment's fourth quarter fiscal 2026 net sales remained flat at $90.1 million, as compared to $89.7 million in the fourth quarter of fiscal 2025. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's fiscal 2026 operating results. Organic revenue increased 8% for the fourth quarter of fiscal 2026, with foreign exchange not having a material impact. The held-for-sale business had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment's operating margin increased to 11.2% in the fourth quarter of fiscal 2026 compared to 6.0% in the fourth quarter of fiscal 2025. The segment's operating margin was favorably impacted by the Exosome Diagnostics divestiture, favorable volume growth, and ongoing profitability initiatives.
The Diagnostics and Spatial Biology segment's full year fiscal 2026 net sales were $336.4 million, a decrease of 3% from $346.3 million for the full year fiscal 2025. Organic growth for the segment was 4%, with foreign currency exchange having a favorable impact of 1%. A business held-for-sale had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment's operating margin was 11.2% in fiscal 2026 compared to 6.2% in fiscal 2025. The segment's operating margin was impacted by the divestiture of Exosome Diagnostics, favorable volume growth, and ongoing profitability initiatives.
About Bio-Techne
Bio‑Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer‑focused brands: R&D Systems™, Bio‑Techne Spatial™, and Bio‑Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision‑making. Bio‑Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements use words and variations of words, such as "will," "plan," "continue," "believe," "outlook," "expect," and "predict." These statements are made as of the date of this press release, are based on current expectations of future events, and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the Company's control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. These risks, uncertainties, and other factors include, without limitation: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning these risks, uncertainties, and other factors, see the section titled "Risk Factors" in the Company's most recent annual report on Form 10-K as filed with the Securities and Exchange Commission. We undertake and we expressly disclaim any obligation to update or revise any forward-looking statements due to new information, changed assumptions, or future events, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.
Non-GAAP Financial Measures:
The Company's financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). This press release contains financial measures that have not been calculated in accordance with GAAP. These non-GAAP measures include:
- Organic revenue and organic revenue growth
- Adjusted gross margin
- Earnings before interest, taxes, depreciation, and amortization (EBITDA)
- Adjusted EBITDA
- Adjusted operating income
- Adjusted operating margin
- Adjusted tax rate
- Adjusted net earnings
- Adjusted diluted earnings per share
These non-GAAP measures should not be considered in isolation or as a substitute for any measure derived in accordance with GAAP and may also be inconsistent with similar measures presented by other companies. Reconciliations of these measures to the applicable most closely comparable GAAP measures, and reasons for the Company's use of these measures, are presented in the attached pages.
Contact: | David Clair, Vice President, Investor Relations | |
612-656-4416 |
BIO-TECHNE CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (In thousands, except per share data) (Unaudited) | ||||||||||||
Quarter Ended | Year Ended | |||||||||||
June 30, | June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Net sales | $ | 321,191 | $ | 316,964 | $ | 1,215,039 | $ | 1,219,635 | ||||
Cost of sales | 109,797 | 118,152 | 415,968 | 429,363 | ||||||||
Gross margin | 211,394 | 198,812 | 799,071 | 790,272 | ||||||||
Operating expenses: | ||||||||||||
Selling, general and administrative | 113,172 | 196,640 | 452,415 | 588,521 | ||||||||
Research and development | 23,945 | 26,032 | 94,766 | 99,496 | ||||||||
Total operating expenses | 137,117 | 222,672 | 547,181 | 688,017 | ||||||||
Operating income | 74,277 | (23,860) | 251,890 | 102,255 | ||||||||
Other income (expense) | (3,596) | 1,001 | (11,210) | (3,792) | ||||||||
Earnings before income taxes | 70,681 | (22,859) | 240,680 | 98,463 | ||||||||
Income taxes | 16,059 | (5,182) | 58,818 | 25,063 | ||||||||
Net earnings | $ | 54,622 | $ | (17,677) | $ | 181,862 | $ | 73,400 | ||||
Earnings per share: | ||||||||||||
Basic | $ | 0.35 | $ | (0.11) | $ | 1.17 | $ | 0.47 | ||||
Diluted | $ | 0.35 | $ | (0.11) | $ | 1.16 | $ | 0.46 | ||||
Weighted average common shares outstanding: | ||||||||||||
Basic | 156,090 | 154,913 | 155,963 | 157,521 | ||||||||
Diluted | 157,025 | 155,757 | 157,009 | 159,717 | ||||||||
BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED GROSS MARGIN AND ADJUSTED GROSS MARGIN PERCENTAGE (In thousands) (Unaudited) | |||||||||||||
Quarter Ended | Year Ended | ||||||||||||
June 30, | June 30, | ||||||||||||
2026 | 2025 | 2026 | 2025 | ||||||||||
Total consolidated net sales | $ | 321,191 | $ | 316,964 | $ | 1,215,039 | $ | 1,219,635 | |||||
Business held-for-sale(1) | — | — | 5,439 | 4,152 | |||||||||
Revenue from recurring operations | $ | 321,191 | $ | 316,964 | $ | 1,209,600 | $ | 1,215,483 | |||||
Gross margin - GAAP | $ | 211,394 | $ | 198,812 | $ | 799,071 | $ | 790,272 | |||||
Gross margin percentage - GAAP | 65.8 | % | 62.7 | % | 65.8 | % | 64.8 | % | |||||
Identified adjustments: | |||||||||||||
Costs recognized upon sale of acquired inventory | $ | — | $ | 197 | $ | — | $ | 751 | |||||
Amortization of intangibles | 9,422 | 10,569 | 37,799 | 44,035 | |||||||||
Stock-based compensation, inclusive of employer taxes | 282 | 288 | 1,534 | 1,298 | |||||||||
Restructuring and restructuring-related costs | 1,049 | 12,141 | 5,805 | 20,094 | |||||||||
Impact of business held-for-sale(1) | — | — | (2,581) | (147) | |||||||||
Adjusted gross margin | $ | 222,147 | $ | 222,007 | $ | 841,628 | $ | 856,303 | |||||
Adjusted gross margin percentage(2) | 69.2 | % | 70.0 | % | 69.6 | % | 70.4 | % | |||||
(1) | June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. |
(2) | Adjusted gross margin percentage excludes both revenue and gross margin of the businesses that met the held-for-sale criteria |
BIO-TECHNE CORPORATION RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (In thousands) (Unaudited) | ||||||||||||
Quarter Ended | Year Ended | |||||||||||
June 30, | June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Net earnings | $ | 54,622 | $ | (17,677) | $ | 181,862 | $ | 73,400 | ||||
Net interest expense (income) | 750 | 1,593 | 5,405 | 4,623 | ||||||||
Depreciation and amortization | 24,169 | 27,111 | 97,359 | 109,903 | ||||||||
Income taxes | 16,059 | (5,182) | 58,818 | 25,063 | ||||||||
EBITDA | 95,600 | 5,845 | 343,444 | 212,989 | ||||||||
Amortization of Wilson Wolf intangible assets | 2,490 | 2,490 | 9,959 | 9,959 | ||||||||
Acquisition related expenses and other | 1,782 | 4,010 | 8,570 | 13,489 | ||||||||
Certain litigation charges | 143 | 1,220 | 5,513 | 41,827 | ||||||||
Stock-based compensation, inclusive of employer taxes | 5,375 | 4,653 | 42,637 | 42,158 | ||||||||
Restructuring and restructuring-related costs | 6,858 | 13,205 | 21,059 | 28,231 | ||||||||
Investment loss and other non-operating loss | 3,695 | — | 5,009 | — | ||||||||
Impairment (Recovery) of assets held-for-sale | — | 84,157 | (6,789) | 80,503 | ||||||||
Impact of business held-for-sale(1) | — | — | 2,573 | 479 | ||||||||
Adjusted EBITDA | $ | 115,943 | $ | 115,580 | $ | 431,975 | $ | 429,635 | ||||
(1) | June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. |
BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED OPERATING INCOME AND ADJUSTED OPERATING MARGIN PERCENTAGE (In thousands) (Unaudited) | |||||||||||||
Quarter Ended | Year Ended | ||||||||||||
June 30, | June 30, | ||||||||||||
2026 | 2025 | 2026 | 2025 | ||||||||||
Total consolidated net sales | $ | 321,191 | $ | 316,964 | $ | 1,215,039 | $ | 1,219,635 | |||||
Business held-for-sale(1) | — | — | 5,439 | 4,152 | |||||||||
Revenue from recurring operations | $ | 321,191 | $ | 316,964 | $ | 1,209,600 | $ | 1,215,483 | |||||
Operating income - GAAP | $ | 74,277 | $ | (23,860) | $ | 251,890 | $ | 102,255 | |||||
Operating income percentage - GAAP | 23.1 | % | (7.5) | % | 20.7 | % | 8.4 | % | |||||
Identified adjustments: | |||||||||||||
Amortization of intangibles | 15,070 | 18,185 | 61,181 | 75,321 | |||||||||
Acquisition related expenses and other | 1,636 | 3,767 | 7,986 | 12,815 | |||||||||
Certain litigation charges | 143 | 1,220 | 5,513 | 41,827 | |||||||||
Stock-based compensation, inclusive of employer taxes | 5,375 | 4,653 | 42,637 | 42,158 | |||||||||
Restructuring and restructuring-related costs | 6,858 | 13,205 | 21,059 | 28,231 | |||||||||
Impairment (Recovery) of assets held-for-sale | — | 84,157 | (6,789) | 80,503 | |||||||||
Impact of business held-for-sale(1) | — | — | 2,573 | 479 | |||||||||
Adjusted operating income | $ | 103,359 | $ | 101,327 | $ | 386,050 | $ | 383,589 | |||||
Adjusted operating margin percentage(2) | 32.2 | % | 32.0 | % | 31.9 | % | 31.6 | % | |||||
(1) | June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. |
(2) | Adjusted operating margin percentage excludes both revenue and operating margin for the businesses that met the held-for-sale |
BIO-TECHNE CORPORATION RECONCILIATION OF NON-GAAP ADJUSTED TAX RATE (In percentages) (Unaudited) | ||||||||||||
Quarter Ended | Year Ended | |||||||||||
June 30, | June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
GAAP effective tax rate | 22.7 | % | 22.7 | % | 24.4 | % | 25.5 | % | ||||
Discrete items | (0.7) | 13.9 | 1.3 | 0.8 | ||||||||
Annual forecast update | 3.7 | (10.3) | — | — | ||||||||
Long-term GAAP tax rate | 25.7 | % | 26.3 | % | 25.7 | % | 26.3 | % | ||||
Rate impact items | ||||||||||||
Stock based compensation | (1.1) | % | (0.9) | % | (2.0) | % | (3.1) | % | ||||
Other | (2.3) | (3.9) | (1.4) | (1.7) | ||||||||
Total rate impact items | (3.4) | % | (4.8) | % | (3.4) | % | (4.8) | % | ||||
Non-GAAP adjusted tax rate | 22.3 | % | 21.5 | % | 22.3 | % | 21.5 | % | ||||
BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED NET EARNINGS AND ADJUSTED EARNINGS PER SHARE (In thousands, except per share data) (Unaudited) | ||||||||||||||
Quarter Ended | Year Ended | |||||||||||||
June 30, | June 30, | |||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||
Net earnings before taxes - GAAP | $ | 70,681 | $ | (22,859) | $ | 240,680 | $ | 98,463 | ||||||
Identified adjustments: | ||||||||||||||
Amortization of intangibles | 15,070 | 18,185 | 61,181 | 75,321 | ||||||||||
Amortization of Wilson Wolf intangible assets | 2,490 | 2,490 | 9,959 | 9,959 | ||||||||||
Acquisition related expenses and other | 1,782 | 4,010 | 8,570 | 13,489 | ||||||||||
Certain litigation charges | 143 | 1,220 | 5,513 | 41,827 | ||||||||||
Stock-based compensation, inclusive of employer taxes | 5,375 | 4,653 | 42,637 | 42,158 | ||||||||||
Restructuring and restructuring-related costs | 6,858 | 13,205 | 21,059 | 28,231 | ||||||||||
Investment loss and other non-operating loss | 3,695 | — | 5,009 | — | ||||||||||
Impairment (Recovery) of assets held-for-sale | — | 84,157 | (6,789) | 80,503 | ||||||||||
Impact of business held-for-sale(1) | — | — | 2,573 | 479 | ||||||||||
Net earnings before taxes - Adjusted | $ | 106,094 | $ | 105,061 | $ | 390,392 | $ | 390,430 | ||||||
Non-GAAP tax rate | 22.3 | % | 21.5 | % | 22.3 | % | 21.5 | % | ||||||
Non-GAAP tax expense | $ | 23,658 | $ | 22,589 | $ | 87,057 | $ | 83,973 | ||||||
Non-GAAP adjusted net earnings | $ | 82,436 | $ | 82,472 | $ | 303,335 | $ | 306,457 | ||||||
Earnings per share - diluted - Adjusted | $ | 0.52 | $ | 0.53 | $ | 1.93 | $ | 1.92 | ||||||
(1) | June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. |
BIO-TECHNE CORPORATION SEGMENT REVENUE (In thousands) (Unaudited) | ||||||||||||
Quarter Ended | Year Ended | |||||||||||
June 30, | June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Protein Sciences segment revenue | $ | 231,194 | $ | 226,472 | $ | 874,620 | $ | 870,245 | ||||
Diagnostics and Spatial Biology segment revenue | 90,141 | 89,705 | 336,365 | 346,263 | ||||||||
Other revenue(1) | — | — | 5,439 | 4,152 | ||||||||
lntersegment revenue | (144) | 787 | (1,385) | (1,025) | ||||||||
Consolidated revenue | $ | 321,191 | $ | 316,964 | $ | 1,215,039 | $ | 1,219,635 | ||||
(1) | June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. |
BIO-TECHNE CORPORATION SEGMENT OPERATING INCOME (In thousands) (Unaudited) | ||||||||||||
Quarter Ended | Year Ended | |||||||||||
June 30, | June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Protein Sciences segment operating income | $ | 97,073 | $ | 98,790 | $ | 359,401 | $ | 370,353 | ||||
Diagnostics and Spatial Biology segment operating income | 10,069 | 5,384 | 37,698 | 21,324 | ||||||||
Segment operating income | 107,142 | 104,174 | 397,099 | 391,677 | ||||||||
Corporate general, selling, and administrative | (3,783) | (2,847) | (11,049) | (8,088) | ||||||||
Adjusted operating income | 103,359 | 101,327 | 386,050 | 383,589 | ||||||||
Amortization of intangibles | (15,070) | (18,185) | (61,181) | (75,321) | ||||||||
Acquisition related expenses and other | (1,636) | (3,767) | (7,986) | (12,815) | ||||||||
Certain litigation charges | (143) | (1,220) | (5,513) | (41,827) | ||||||||
Stock-based compensation, inclusive of employer taxes | (5,375) | (4,653) | (42,637) | (42,158) | ||||||||
Restructuring and restructuring-related costs | (6,858) | (13,205) | (21,059) | (28,231) | ||||||||
(Impairment) Recovery of assets held-for-sale | — | (84,157) | 6,789 | (80,503) | ||||||||
Impact of business held-for-sale(1) | — | — | (2,573) | (479) | ||||||||
Operating income | $ | 74,277 | $ | (23,860) | $ | 251,890 | $ | 102,255 | ||||
(1) | June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. |
BIO-TECHNE CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) | ||||||
June 30, | June 30, | |||||
2026 | 2025 | |||||
ASSETS | ||||||
Cash and equivalents | $ | 264,712 | $ | 162,186 | ||
Accounts receivable, net | 216,585 | 206,876 | ||||
Inventories | 195,744 | 189,446 | ||||
Current assets held-for-sale | — | 12,332 | ||||
Other current assets | 67,360 | 37,460 | ||||
Total current assets | 744,401 | 608,300 | ||||
Property and equipment, net | 231,836 | 245,719 | ||||
Right of use assets | 67,333 | 73,399 | ||||
Goodwill and intangible assets, net | 1,278,820 | 1,346,534 | ||||
Other assets | 264,336 | 283,916 | ||||
Total assets | $ | 2,586,726 | $ | 2,557,868 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
Accounts payable and accrued expenses | $ | 105,075 | $ | 116,765 | ||
Contract liabilities | 36,072 | 32,571 | ||||
Income taxes payable | 3,593 | 10,770 | ||||
Operating lease liabilities - current | 14,935 | 14,098 | ||||
Other current liabilities | 4,025 | 1,645 | ||||
Total current liabilities | 163,700 | 175,849 | ||||
Deferred income taxes | 19,308 | 6,169 | ||||
Long-term debt obligations | 200,000 | 346,000 | ||||
Operating lease liabilities | 74,152 | 83,960 | ||||
Other long-term liabilities | 21,345 | 27,082 | ||||
Stockholders' equity | 2,108,221 | 1,918,808 | ||||
Total liabilities and stockholders' equity | $ | 2,586,726 | $ | 2,557,868 | ||
BIO-TECHNE CORPORATION CONDENSED CONSOLIDATED CASH FLOWS (In thousands) (Unaudited) | ||||||
Year Ended | ||||||
June 30, | ||||||
2026 | 2025 | |||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||
Net earnings | $ | 181,862 | $ | 73,400 | ||
Adjustments to reconcile net earnings to net cash provided by operating activities | ||||||
Depreciation and amortization | 97,359 | 109,903 | ||||
Costs recognized on sale of acquired inventory | — | 751 | ||||
Deferred income taxes | 13,196 | (51,107) | ||||
Stock-based compensation expense | 41,365 | 40,833 | ||||
(Gain) Loss on equity method investment | (887) | (938) | ||||
Asset impairment restructuring | 3,914 | 21,312 | ||||
Recovery of assets held-for-sale | (6,789) | 80,503 | ||||
Other operating activities | (37,947) | 12,899 | ||||
Net cash provided by (used in) operating activities | 292,073 | 287,556 | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||
Proceeds from sale of available-for-sale investments | — | 1,085 | ||||
Additions to property and equipment | (28,850) | (31,006) | ||||
Distributions from Wilson Wolf | 6,043 | 7,291 | ||||
Investment in Spear Bio | — | (15,000) | ||||
Proceeds from sale of assets held-for-sale | 4,617 | 2,447 | ||||
Net cash provided by (used in) investing activities | (18,190) | (35,183) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||
Cash dividends | (49,916) | (50,391) | ||||
Proceeds from stock option exercises | 80,618 | 51,739 | ||||
Long-term debt activity, net | (146,000) | 27,000 | ||||
Repurchases of common stock | (41,675) | (275,731) | ||||
Taxes paid on RSUs and net share settlements | (12,141) | (6,522) | ||||
Net cash provided by (used in) financing activities | (169,114) | (253,905) | ||||
Effect of exchange rate changes on cash and cash equivalents | (2,243) | 11,927 | ||||
Net increase (decrease) in cash and cash equivalents | 102,526 | 10,395 | ||||
Cash and cash equivalents at beginning of period | 162,186 | 151,791 | ||||
Cash and cash equivalents at end of period | $ | 264,712 | $ | 162,186 | ||
Use of Non-GAAP Financial Measures:
This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. Investors are encouraged to review the reconciliations of non-GAAP financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.
Our non-GAAP financial measure of organic revenue and organic revenue growth represent revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, as well as the impact of businesses held-for-sale. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods.
Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, and restructuring and restructuring-related costs. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.
The Company's non-GAAP adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition.
The Company's non-GAAP adjusted EBITDA and adjusted net earnings, in total and on a per share basis, also excludes gains and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.
SOURCE Bio-Techne Corporation
Share this article